Israel has recently been in the news after the government issued its long-delayed final approval of medical cannabis exports. Still, Israel’s most important cannabis export will arguably continue to be clinical data. While research in the United States remains strangled in a Schedule 1 chokehold, Israelis are diligently engaged in cannabis R&D, fueled by the country’s relatively supportive regulatory climate, well-established research infrastructure, and hyperactive entrepreneurial spirit. Read more on Forbes.com